All In Biotech

Drug Trial Radar · NCT04834427

Safety and Efficacy Evaluation of S (+) - Ketamine in Children

Safety and Efficacy Evaluation of S (+) -Ketamine for Postoperative Acute Pain in Children in Perioperative Settings: A Multicenter, Randomized, Open-label, Active Controlled Pragmatic Clinical Trial

Last checked: Nov 19, 2026Latest source record: Mar 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,000

Planned (sponsor's estimate)

Start

Apr 20, 2022

Primary completion

Dec 1, 2024

Study completion Dec 4, 2024

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Southern Medical University, China; Beijing Children's Hospital; Shanghai Children's Medical Center; Hunan Children's Hospital
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, open-label, active controlled pragmatic clinical trial that evaluates the safety and efficacy of S (+) -ketamine for postoperative acute pain in children in perioperative settings.

Conditions

  • S-ketamine
  • Esketamine
  • Acute Pain
  • Postoperative Pain
  • Analgesia
  • Hyperalgesia
  • Delirium
  • Depression, Anxiety
  • Children

Interventions

  • Conventional therapy + S (+)-KetamineDrug

    In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions. Recommended use and dosage of S (+)-Ketamine: 1. Intravenous injection:Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h. 2. Intramuscular injection:The dose is 2\~4 mg/kg.

  • Conventional therapyDrug

    Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The area under the broken line of FLACC scale scoreTime frame: Hour 0-48 after surgery
  2. The area under the broken line of Numerical Rating Scale scoreTime frame: Hour 0-48 after surgery
  3. Opioid consumptionTime frame: Hour 0-48 after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.